GlassScriptPhysician profile
Christopher Dominick Ellis
NPI 1366026361
$7,221.12
in general payments reported to CMS, 2019-2025
28 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $978 · 2023: $1,302 · 2024: $2,131 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,694 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,694.38 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,070.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $966.88 | 2022-2025 | Farxiga, Brilinta, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $642.92 | 2021-2025 | Lifevest |
| Amgen INC. | $635.80 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $615.13 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.68 | 2021-2025 | Jardiance |
| Pfizer INC. | $397.81 | 2021-2025 | |
| Boston Scientific Corporation | $303.02 | 2023-2025 | Watchman Flx, Bodyguardian |
| Novo Nordisk INC | $290.23 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $268.21 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $217.95 | 2022-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $164.41 | 2024-2025 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $163.85 | 2023-2025 | Injectafer |
| Esperion Therapeutics, INC. | $157.78 | 2021-2025 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $137.40 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $64.86 | 2025 | |
| Tactile Systems Technology INC | $64.29 | 2025 | Flexitouch Plus, Nimbl |
| Kiniksa Pharmaceuticals International, Plc | $60.25 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $51.58 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $49.06 | 2024-2025 | Onpattro |
| Bridgebio Pharma, INC. | $41.55 | 2025 | Attruby |
| Philips North America LLC | $20.94 | 2023 | |
| Amarin Pharma, INC. | $19.08 | 2021 | |
| Lilly USA, LLC | $18.95 | 2025 | |
| Acarix USA INC. | $16.78 | 2023 | Cadscor System |
| Biotronik INC. | $16.57 | 2022 | |
| Altathera Pharmaceuticals LLC | $14.71 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.